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ARTICLE
Genetic Variation in the CCL18-CCL3-CCL4 Chemokine
Gene Cluster Influences HIV Type 1 Transmission
and AIDS Disease Progression
William S. Modi,* James Lautenberger, Ping An, Kevin Scott, James J. Goedert, Gregory D. Kirk,
Susan Buchbinder, John Phair, Sharyne Donfield, Stephen J. O’Brien, and Cheryl Winkler
CCL3 (MIP-1a), CCL4 (MIP-1b), and CCL18 (DC-CK1/PARC/AMAC-1) are potent chemoattractants produced by mac-
rophages, natural killer cells, fibroblasts, mast cells, CD4+ T cells, and CD8+ T cells. CCL3 and CCL4 are natural ligands
for the primary human immunodeficiency virus type 1 (HIV-1) coreceptor CCR5 and are also known to activate and
enhance the cytotoxicity of natural killer cells. Genomic DNAs from 13,000 participants enrolled in five United States–
based natural-history cohorts with acquired immunodeficiency syndrome (AIDS) were genotyped for 21 single-nucleotide
polymorphisms (SNPs) in a 47-kb interval on chromosome 17q12 containing the genes CCL3, CCL4, and CCL18. All 21
SNPs were polymorphic in African Americans (AAs), whereas 7 of the 21 had minor-allele frequencies !0.01 in European
Americans (EAs). Substantial linkage disequilibrium was observed in a 37-kb interval containing 17 SNPs where many
pairwise D′ values exceeded 0.70 in both racial groups, but particularly in EAs. Four and three haplotype blocks were
observed in AAs and EAs, respectively. Blocks were strongly correlated with each other, and common haplotype diversity
within blocks was limited. Two significant associations are reported that replicate an earlier study. First, among AA
members of the AIDS Link to the Intravenous Experience cohort of injection drug users, frequencies of three correlated
SNPs covering 2,231 bp in CCL3 were significantly elevated among highly exposed, persistently HIV-1–uninfected in-
dividuals compared with HIV-1–infected seroconvertors ( ). Second, seven highly correlated SNPs spanningPp .02–.03
36 kb and containing all three genes were significantly associated with more-rapid disease progression among EAs enrolled
in the Multicenter AIDS Cohort Study cohort ( ). These results reiterate the importance of chemokine genePp .01–.02
variation in HIV-1/AIDS pathogenesis and emphasize that localized linkage disequilibrium makes the identification of
causal mutations difficult.
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The heterogeneity among individuals in their suscepti-
bility to HIV type 1 (HIV-1) infection and the variable rates
of disease progression among HIV-1–infected individuals
are the results of many factors, including viral virulence,
environmental conditions, age, and host genetics. Host
antiviral immunity can act at different levels, including
the inhibition of viral attachment, entry, or assembly, and
may include various responses to viral infection, such as
cytotoxic T-cell response, the generation of noncytolytic
factors such as cytokines, and antibody production.1
AIDS restriction genes have been defined in which al-
lelic variation has been shown to influence infection or
disease progression. These include genes encoding che-
mokine receptors, chemokines, human leukocyte antigen,
and cytokines and genes involved with innate or acquired
immunity.2 Chemokines became prominent in HIV-1 re-
search when the culture supernatants of CD8 T cells dem-
onstrated HIV-1 suppressor activity,3,4 and this activity was
shown to be attributable to three CC chemokines—
namely, RANTES (CCL5), MIP-1a (CCL3), and MIP-1b
(CCL4).5 Chemokines are a group of low-molecular-
weight, basic, heparin-binding proteins that mediate an
array of homeostatic and inflammatory processes. The
amino acid sequences contain four conserved cysteine res-
idues, and these molecules signal through receptors be-
longing to the G-protein–coupled seven-transmembrane
domain receptor family.6 Over 50 chemokine genes are
assigned to two major subgroups: the a (or C#C) and the
b (or CC) subgroups. Sixteen members of the CC gene
family have been assigned to chromosome 17q12, and
many of these genes exhibit extreme sequence conser-
vation, suggesting recent duplication and selection for
conserved function in their evolutionary histories.7,8
The CCL3 and CCL4 chemokine genes, along with
CCL18, are located within 40 kb of each other. SNPs in
the CCL3 gene were evaluated in two previous HIV-1 ep-
idemiological studies. Four CCL3 SNPs were not signifi-
cantly associated with HIV-1 infection in a Japanese pop-
ulation,9 whereas a haplotype containing two CCL3 intron
1 SNPs was associated with resistance to HIV-1 acquisition
in African Americans (AAs) and with accelerated progres-
sion to AIDS in European Americans (EAs).10 Given the
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Figure 1. Molecular map of the CCL18, CCL3, and CCL4 genes. Each gene has three exons, depicted as blackened boxes, and SNPs are
numbered 1–21. The distance between SNPs 1 and 21 is 47,637 bp. Below the map are pairwise plots and haplotype blocks obtained′D
from HAPLOVIEW for 420 AAs (A) and 972 EAs (B) (in panel B, seven tracks are blank because of MAFs !0.01). Dark-red squares signify
high D′ values, light-blue squares indicate high D′ values with low LOD scores, and light-red and white squares indicate low D′ values.
Block boundaries are based on the 95% CIs for D′.23 Panels C and D show the structure of haplotype blocks found in AAs and EAs,
respectively. Haplotype-tagging SNPs identified by HAPLOVIEW are indicated by arrowheads. Numbers below the blocks are interblock,
multiallelic D′ values.
obvious role played by CCL3 and CCL4 in HIV-1/AIDS
pathogenesis and the availability of high-density SNP
maps for population-based association analyses, we ex-
amined, in the present study, variation in 21 SNPs span-
ning 47 kb of genomic DNA containing the CCL18, CCL3,
and CCL4 genes in 13,000 participants enrolled in five
United States–based longitudinal HIV-1/AIDS cohorts.
Two primary questions were addressed in the study. First,
what is the extent and nature of SNP and haplotype var-
iation in and around these three genes in two racial
groups? Second, do genetic variants exist in these genes
that influence HIV-1 infection and/or AIDS disease
progression?
Material and Methods
Participants and Clinical Outcomes
Participants were enrolled in five longitudinal cohorts. The AIDS
Link to the Intravenous Experience (ALIVE) is a community-based
cohort of adult injection drug users in Baltimore.11 The racial
distribution is 92.4% AA and 7.6% EA. The Hemophilia Growth
and Development Study (HGDS) is a multicenter prospective
study that enrolled children with hemophilia.12 The cohort con-
sists of 126 HIV-1–uninfected and 207 HIV-1–infected children
who were exposed to HIV-1 through blood products between
1982 and 1983. The racial distribution is 72% EA, 15% Hispanic,
and 11% AA. The Multicenter Hemophiliac Cohort (MHCS) is a
prospective study that enrolled persons with hemophilia.13 The
racial distribution is 90% EA, 6% AA, and 3% Hispanic. The Mul-
ticenter AIDS Cohort Study (MACS) is a longitudinal study of
men who have sex with men (MSM) from four U.S. cities: Chi-
cago, Baltimore, Pittsburgh, and Los Angeles.14,15 The racial dis-
tribution is 83.3% EA, 10% AA, and 5% Hispanic. The San Fran-
cisco City Clinic Study (SFCC) is a cohort of MSM originally
enrolled in a hepatitis B study in 1978–1980.16 The cohort consists
of 211 individuals, 203 of whom are EA. The majority of subjects
were enrolled into the cohorts during the following years: ALIVE,
1988–1989; MACS, 1984–1985; MHCS, 1982–1985; and SFCC,
1978–1980.
All individuals used for association analyses were (1) uninfected
individuals who have undocumented levels of exposure but who
122 The American Journal of Human Genetics Volume 79 July 2006 www.ajhg.org
Table 1. MAFs and Gene Positions for 21 SNPs in the CCL18, CCL3, and CCL4
Chemokine Genes
SNP dbSNP
MAFa
Location Position
Inter-SNP
Distanceb
(bp)AA EA
1 rs712040 .497 .108 CCL18 promoter 6111 C/T …
2 rs2015086 .384 .13 CCL18 promoter 86 C/T 6,025
3 rs2015070 .039 .087 CCL18 intron 1 81 A/G 166
4 rs712043 .058 .302 CCL18 intron 1 4965 C/T 4,884
5 rs854472 .062 .304 CCL18 intron 1 5906 A/G 941
6 rs1719220 .055 .277 CCL18 3′ UTR 12575 A/G 6,669
7 rs1634481 .055 .271 CCL3 3′ UTR 11730 A/G 1,398
8 rs1719127 .121 .004 CCL3 3′ UTR 1829 A/G 9,901
9 rs8951 .081 .218 CCL3 exon 3 1685 C/T 144
10 ss46566437 .083 .004 CCL3 exon 3 1342 G/T (E79D) 343
11 rs1719130 .194 .24 CCL3 intron 2 1159 C/T 183
12 rs1130371 .154 .234 CCL3 exon 2 868 C/T (P60P) 291
13 rs1719133 .065 .005 CCL3 intron 1 740 A/G 128
14 rs1719134 .151 .24 CCL3 intron 1 459 A/G 281
15 ss46566438 .083 .005 CCL3 intron 1 113 C/T 346
16 ss46566439 .08 .004 CCL3 promoter 891 T/C 1,002
17 rs1634498 .077 .003 CCL3 promoter 2021 C/T 1,131
18 rs1634507 .113 .237 CCL4 promoter 5725 A/C 6,149
19 rs1719144 .054 .222 CCL4 intron 1 104 A/T 5,829
20 rs1719146 .032 0 CCL4 exon 2 663 C/T (T39T) 558
21 rs1719153 .077 .233 CCL4 3′ UTR 1931 A/T 1,268
a MAFs were determined by genotyping 675–1,116 AAs and 978–2,054 EAs for any given SNP.
b Distance from the previous SNP. The total distance between SNPs 1 and 21 is 47,637 bp.
Table 2. Primers and Probes and the
Restriction Enzymes Used in Genotyping Assays
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
belong to an HIV-1 risk group; (2) high-risk, exposed, uninfected
(HREU) individuals with documented high risk for HIV-1 expo-
sure; (3) HIV-1–positive seroconvertors, with seroconversion
dates estimated as the midpoint between the last visit with se-
ronegative test results and the first visit with seropositive test
results; or (4) seroprevalent individuals who were infected with
HIV-1 at study enrollment. The HREU participants were exposed
to HIV-1 by receptive anal intercourse with multiple partners,15,16
by transfusion with nonheated units of factor VIII or IX between
1982 and 1983,17 or by injection drug use.11 A concise summary
of these cohorts is available.18 Over 3,000 individuals were ge-
notyped, and the data were used to estimate allele frequencies,
but genotypes from only 1,326 individuals were used in disease
association analyses: 449 AAs (159 seronegative individuals and
290 seroconvertors) and 877 EAs (216 seronegative individuals
and 661 seroconvertors). Since antiretroviral treatment history
was unavailable for a majority of subjects, participants were cen-
sored for highly active antiretroviral therapy (HAART), instead of
the effects of HAART being adjusted for in the models.19 The
censoring date was the earlier of two dates: the last recorded
follow-up visit or December 31, 1995, for the MACS, MHCS,
HGDS, and SFCC cohorts and the last recorded visit or July 31,
1997, for the ALIVE cohort. A later censoring date was used for
the ALIVE cohort because administration of HAART was de-
layed.20 The median follow-up times were 5.1, 7.3, 10.7, and
13.4 years for the ALIVE, MACS, MHCS, and SFCC cohorts,
respectively.
Three separate end points reflecting advancing AIDS patho-
genesis were considered for seroconvertors: (1) the Centers for
Disease Control and Prevention (CDC) definition of AIDS in 1993
(AIDS-93): HIV-1 infection plus a CD4 T cell count of !200/ml
or AIDS-defining conditions21; (2) the CDC definition of AIDS in
1987 (AIDS-87): HIV-1 infection plus AIDS-defining illness22; and
(3) AIDS-related death during follow-up of an HIV-1–infected
patient.
SNP Discovery and Genotyping
The CCL18, CCL4, and CCL3 genes are located within 40 kb of
one another at chromosome 17q12 (fig. 1). Each gene contains
three exons and two introns.24 SNPs were identified by using the
SSCP technique, by resequencing the CCL3 and CCL4 genes, or
by surveying the dbSNP database (build 110). For SSCP or rese-
quencing, 12 different genomic regions covering 13,000 bp were
analyzed on DNAs from 36 unrelated EAs and 36 unrelated AAs
presenting with various HIV-1/AIDS phenotypes. A total of 21
SNPs were genotyped (table 1) by use of either PCR-RFLP or
TaqMan allelic discrimination (Applied Biosystems) techniques
(table 2).25
Statistical Analyses
Allele frequencies and genotype frequencies were calculated and
tests for Hardy-Weinberg equilibrium were performed using SAS
Genetics software (SAS Institute). Unphased diploid genotype
data were partially phased by use of PHASE,26 and the output
from PHASE was input into HAPLOVIEW27 for pairwise D′ and r2
calculation, haplotype estimation, and haplotype-block construc-
tion. Comparisons of allele, genotype, and haplotype frequen-
cies between the seronegative HREU individuals and the HIV-1–
infected seroconvertors were done with Fisher’s exact test or lo-
gistic regression by use of SAS. Cox proportional hazards regres-
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Table 3. Survival Analyses of Progression to Three AIDS End Points for CCL18, CCL3, and CCL4 SNPs and One Haplotype
Group and SNP or Haplotype
AIDS-93 AIDS-87 Death
NE RH (95% CI) P NE RH (95% CI) P NE RH (95% CI) P
AAs in all cohorts ( ):np 290 … … … … … … … … …
rs712040 124 1.01 (.60–1.52) .96 57 .86 (.49–1.52) .6 33 1.37 (.61–.50) .45
rs2015086 125 1.09 (.75–1.57) .66 59 .95 (.56–1.61) .84 32 1.12 (.55–2.28) .76
rs2015070 125 1.11 (.55–2.22) .77 59 .79 (.28–2.23) .65 34 .71 (.17–3.06) .65
rs712043 125 1.18 (.72–1.94) .5 59 1.09 (.53–2.25) .81 34 .75 (.26–2.15) .59
rs854472 128 1.11 (.68–1.82) .68 61 1.03 (.50–2.12) .93 35 .73 (.25–2.07) .55
rs1719220 130 1.26 (.75–2.11) .39 63 1.18 (.55–2.53) .68 36 .98 (.34–2.81) .97
rs1634481 129 .06 (.70–2.01) .52 63 1.10 (.51–2.38) .8 36 .92 (.32–2.65) .88
rs1719127 131 .96 (.62–1.51) .87 62 .84 (.43–1.62) .6 35 1.18 (.53–2.64) .68
rs8951 131 1.34 (.85–2.11) .2 61 1.26 (.66–2.43) .48 35 1.69 (.75–3.81) .21
ss46566437 132 .97 (.58–1.61) .9 62 .77 (.36–1.65) .5 35 .77 (.27–2.19) .62
rs1719130 125 1.3 (.89–1.94) .18 57 1.27 (.73–2.20) .4 32 1.29 (.62–2.68) .49
rs1130371 131 1.34 (.91–1.94) .14 62 1.21 (.69–2.11) .5 35 .90 (.41–1.95) .78
rs1719133 132 .91 (.52–1.59) .74 62 1.09 (.51–2.32) .82 35 1.16 (.45–3.02) .76
rs1719134 125 1.25 (.83–1.88) .29 56 .96 (.51–1.82) .91 32 .79 (.32–1.96) .62
ss46566438 129 .90 (.53–1.53) .69 60 .85 (.40–1.81) .67 35 .80 (.28–2.28) .68
ss46566439 130 .92 (.54–1.56) .75 60 .65 (.28–1.52) .32 35 .91 (.32–2.59) .86
rs1634498 129 1.02 (.62–1.69) .93 60 1.13 (.56–2.26) .74 34 1.29 (.53–3.16) .58
rs1634507 130 1.53 (1.01–2.34) .05* 60 1.33 (.71–2.50) .37 35 .64 (.24–1.69) .36
rs1719144 129 1.52 (.91–2.52) .11 60 1.34 (.61–2.95) .47 34 .66 (.19–2.31) .52
rs1719146 126 2.37 (1.11–5.06) .03* 59 2.72 (.99–7.49) .05* 34 1.39 (.30–6.37) .67
rs1719153 129 1.55 (.96–2.48) .07 62 1.60 (.81–3.13 .17 35 .71 (.24–2.13) .54
Haplotype [block 3-.071] 123 1.37 (.77–2.34) .21 60 1.19 (.55–2.47) .38 33 .84 (.33–2.26) .51
rs1719146 104 2.38 (1.12–5.04) .02* 46 2.72 (.97–7.56) .06 22 2.17 (.47–9.97) .32
EAs in all cohorts ( ):np 661 … … … … … … … … …
rs712040 406 .96 (.75–1.23) .75 293 .95 (.71–1.28) .74 250 .93 (.66–1.29) .65
rs2015086 413 .96 (.76–1.21) .72 299 .98 (.75–1.29) .89 256 .97 (.72–1.31) .85
rs2015070 406 .90 (.69–1.17) .43 293 .80 (.58–1.12) .19 250 .82 (.57–1.17) .27
rs712043 411 1.09 (.89–1.32) .4 298 1.16 (.92–1.46) .22 255 1.08 (.84–1.39) .55
rs854472 408 1.11 (.91–1.35) .3 294 1.21 (.96–1.53) .11 250 1.12 (.87–1.44) .38
rs1719220 410 1.04 (.85–1.27) .71 298 1.09 (.86–1.37) .48 253 .97 (.75–1.24) .79
rs1634481 396 1.06 (.87–1.30) .55 286 1.14 (.90–1.44) .29 240 .99 (.77–1.29) .96
rs1719127a … … … … … … … … …
rs8951 409 1.15 (.95–1.40) .15 298 1.30 (1.03–1.63) .03* 262 1.06 (.83–1.36) .64
ss46566437 … … … … … … … … …
rs1719130 400 1.24 (1.01–1.51) .04* 289 1.39 (1.10–1.76) .01* 250 1.25 (.97–1.60) .09
rs1130371 414 1.17 (.97–1.43) .11 302 1.33 (1.06–1.67) .01* 263 1.15 (.90–1.47) .26
rs1719133 … … … … … … … … …
rs1719134 418 1.18 (.98–1.44) .09 304 1.34 (1.07–1.68) .01* 264 1.17 (.92–1.49) .21
ss46566438 … … … … … … … … …
ss46566439 … … … … … … … … …
rs1634498 … … … … … … … … …
rs1634507 405 1.14 (.93–1.38) .21 297 1.23 (.98–1.54) .08 257 1.07 (.83–1.37) .61
rs1719144 392 1.20 (.98–1.47) .07 287 1.32 (1.05–1.67) .02* 252 1.09 (.85–1.41) .49
rs1719146 … … … … … … … … …
rs1719153 409 1.19 (.98–1.45) .08 297 1.33 (1.06–1.68) .01* 253 1.20 (.94–1.54) .15
EAs in MACS cohort ( ):np 403 … … … … … … … … …
rs712043 248 1.14 (.89–1.47) .3 183 1.38 (1.02–1.85) .04* 159 1.18 (.86–1.62) .31
rs854472 248 1.15 (.89–1.48) .28 181 1.41 (1.05–1.91) .02* 156 1.20 (.87–1.65) .27
rs1634481 246 1.08 (.83–1.39) .57 179 1.27 (.94–1.71) .12 153 1.01 (.73–1.39) .95
rs8951 243 1.21 (.94–1.57) .14 182 1.43 (1.06–1.91) .02* 162 1.12 (.82–1.53) .46
rs1719130 241 1.19 (.92–1.54) .18 179 1.40 (1.04–1.88) .02* 158 1.22 (.89–1.68) .21
rs1130371 245 1.22 (.95–1.57) .13 184 1.41 (1.06–1.89) .02* 162 1.15 (.85–1.57) .37
rs1719134 250 1.22 (.95–1.57) .11 187 1.42 (1.07–1.90) .02* 164 1.19 (.87–1.62) .28
rs1634507 238 1.19 (.92–1.54) .18 180 1.32 (.99–1.78) .06 157 1.12 (.82–1.54) .47
rs1719144 228 1.19 (.92–1.55) .19 172 1.42 (1.05–1.91) .02* 153 1.13 (.82–1.56) .44
rs1719153 247 1.22 (.95–1.57) .12 183 1.45 (1.08–1.94) .01* 158 1.26 (.92–1.73) .15
NOTE.—End points were assessed using Cox proportional hazards regression under a dominant genetic model (results include CCL5 covariates listed in the “Material
and Methods” section). n p number of seroconvertors; NE p number of events. P values .05 are indicated by an asterisk (*).
a Results not reported for seven SNPs with near-zero MAFs in EAs.
sion and Kaplan-Meier survival statistics assessed rates of disease
progression among seroconvertors. Regression and survival anal-
yses were performed twice—once by using each SNP or haplotype
alone and once by including three SNPs from CCL5 (RANTES) as
covariates: RANTES-3′ 222, RANTES-In1.1 (rs2280789), and RAN-
TES-(403) (rs2107538).28,29 Participants were stratified by sex (re-
sults are shown for males only) and age at HIV-1 seroconversion:
!20 years, 20–40 years, and 140 years. The results stratified by
age were included in the model and appear in table 3.
Results
Twenty-one SNPs covering a 47,637-bp region containing
CCL18, CCL3, and CCL4 (fig. 1) were genotyped in up to
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Table 4. A Comparison of CCL18, CCL3, and CCL4 Dominant Genotype Frequencies between
Seroconvertors (HIV+) and HREU Participants (HIV-1 Seronegative)
SNP
AAs in All Cohorts EAs in All Cohortsa
HIV
( )np 290
HIV-1
Seronegative
( )np 79 OR (95% CI) P
HIV
( )np 661
HIV-1
Seronegative
( )np 128 OR (95% CI) P
rs712040 .714 .708 1.03 (.58–1.82) 1 .189 .183 1.04 (.64–1.70) 1
rs2015086 .599 .569 1.13 (.67–1.90) .69 .236 .227 1.05 (.67–1.66) .91
rs2015070 .076 .118 .61 (.27–1.39) .25 .165 .164 1.00 (.60–1.69) 1
rs712043 .129 .149 .84 (.39–1.80) .69 .498 .461 1.15 (.79–1.69) .51
rs854472 .135 .143 .93 (.44–1.98) .85 .505 .461 1.19 (.82–1.75) .38
rs1719220 .124 .127 .98 (.46–2.07) 1 .459 .448 1.05 (.71–1.54) .85
rs1634481 .125 .115 1.10 (.51–2.39) 1 .453 .437 1.06 (.73–1.57) .77
rs1719127 .207 .278 .68 (.38–1.19) .22 … … … …
rs8951 .176 .127 1.47 (.71–3.04) .39 .396 .353 1.20 (.82–1.77) .38
ss46566437 .153 .241 .57 (.31–1.04) .09 … … … …
rs1719130 .345 .329 1.08 (.62–1.86) .89 .398 .423 .90 (.61–1.32) .62
rs1130371 .295 .304 .96 (.56–1.65) .89 .417 .409 1.03 (.71–1.50) .92
rs1719133 .115 .179 .60 (.30–1.18) .13 … … … …
rs1719134 .263 .316 .77 (.45–1.33) .39 .414 .411 1.01 (.70–1.46) 1
ss46566438 .151 .244 .55 (.30–1.01) .06 … … … …
ss46566439 .143 .241 .53 (.29–.97) .04* … … … …
rs1634498 .154 .208 .69 (.37–1.31) .3 … … … …
NOTE.—ORs, 95% CIs, and P values were obtained using Fisher’s exact test. P values .05 are indicated by an asterisk
(*). n p number of individuals examined.
a Results are not reported for seven SNPs with near-zero MAFs. Individuals homozygous for the CCR5D32 allele30
were not included.
3,158 participants. Three SNPs occurred within coding
regions as follows: (1) ss46566437 at 1342GrT changes
amino acid position 79 (E79D) in exon 3 of the CCL3 gene,
(2) rs1130371 at 868CrT is a silent substitution (P60P)
in exon 2 of the CCL3 gene, and (3) rs1719146 at
663CrT is a silent substitution (T39T) in exon 2 of the
CCL4 gene. All other SNPs were noncoding and were
found in promoter regions, introns, and intergenic areas
(fig. 1 and table 1). Of the 21 SNPs, 7 had minor-allele
frequencies (MAFs) !0.01 in EAs and were excluded in all
subsequent analyses of EAs, whereas all 21 SNPs had MAFs
10.03 in AAs and were retained in analyses of AAs (ta-
ble 1).
Linkage Disequilibrium (LD) and Haplotype Analyses
Pairwise D′ values for AAs and EAs are shown (fig. 1A and
1B). In AAs, the three SNPs at both (5′ and 3′) ends of the
region had much lower D′ values than did the 15 SNPs in
the middle. Similarly, in EAs, the three SNPs at the 5′ end
had lower D′ values than the remaining 11 SNPs. In ad-
dition, 16 (7.6%) of 211 pairwise r2 values exceeded 0.70
in AAs, whereas 30 (33%) of 91 pairwise r2 values exceeded
0.70 in EAs. These higher r2 values in EAs are reflected by
the limited range in MAFs (0.218–0.304) for all but the
three SNPs at the 5′ end, whereas MAFs in AAs showed
a greater range across the entire region (0.032–0.497) (ta-
ble 1).
Haplotype-block analysis identified four blocks in AAs,
which were !1 kb, 1 kb, 3 kb, and 7 kb in size, and three
blocks in EAs, which were 6 kb, !1 kb, and 28 kb in size
(fig. 1C and 1D). Diversity within each block was limited;
only block 3 in AAs had more than two common hap-
lotypes with frequencies exceeding 5%. In addition, mul-
tiallelic D′ values between blocks ranged from 0.81 to 0.93,
indicating extensive disequilibrium between blocks in
both AAs and EAs. Although there are recombinant hap-
lotypes in AA blocks 3 and 4 and in EA block 3, only one
common haplotype (frequency 10.05) contains informa-
tion that is not available from analyzing the individual
SNPs. This haplotype is found in AA block 3 at a frequency
of 0.071 and is named “AA haplotype [block 3-0.071].” This
haplotype is a recombinant containing only a portion
of the minor alleles from rs1719130, rs1130371, and
rs1719134 (fig. 1C). On the other hand, all other common
haplotypes contain all minor alleles for at least one SNP
and are thus redundant with that SNP. For example, AA
haplotype [block 3-0.090] contains a portion of alleles from
three SNPs but contains all alleles from SNPs ss46566437,
ss46566438, and ss46566439 (fig. 1C).
Disease Associations
The influence of each SNP and the single unique haplo-
type—AA haplotype [block 3-0.071]—on HIV-1 transmis-
sion was examined by comparing HREU individuals with
HIV-1–infected seroconvertors after stratifying by race (ta-
bles 4 and 5). Among AAs from all cohorts combined,
ss46566439, occurring in CCRL3, had significantly ele-
vated genotype frequency in the 79 HREU individuals (fre-
quency 0.241) compared with the 296 HIV-1–positive
seroconvertors (frequency 0.143) ( ). To minimizePp .04
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Table 5. A Comparison of CCL18, CCL3, and CCL4 Dominant Genotype and Haplotype Frequencies between Seroconvertors
(HIV+) and HREU Participants (HIV-1 Seronegative)
SNP or
Haplotype
AAs in ALIVE Cohorta AAs in All Cohorts EAs in MHCS Cohort
HIV
HIV-1
Seronegative OR (95% CI) P
HIV
( )np 296
HIV-1
Seronegative
( 9)np 7 OR (95% CI) P
HIV
( )np 170
HIV-1
Seronegative
( )np 25 OR (95% CI) P
ss46566437 .143 .26 .47 (.25–.90) .03* … … … … … … … …
ss46566438 .145 .264 .48 (.25–.89) .03* … … … … … … … …
ss46566439 .135 .26 .44 (.23–.84) .02* … … … … … … … …
Haplotype
[block 3-.071] .126 .096 1.31 (.49–3.52) .61 .126 .096 1.35 (.57–3.21) .49 … … … …
rs2105086 … … … … … … … … .176 .4 .32 (.13–.78) .02*
NOTE.—ORs, 95% CIs, and P values were obtained using Fisher’s exact test for SNPs and logistic regression for the haplotype. P values .05 are indicated by an asterisk
(*). n p number of individuals examined.
a HIV, for SNPs and 296 for the haplotype; HIV-1 Seronegative, for SNPs and 79 for the haplotype.np 238 np 73
inherent variability resulting from the combining of co-
horts, the predominant AA cohort (the injection-drug-
using ALIVE cohort) was considered separately. Among
AAs in the ALIVE cohort, three CCL3 SNPs—ss46566437,
ss46566438, and ss46566439—were significantly elevated
in frequency in the 73 HREU individuals compared with
the 238 HIV-1–infected seroconvertors ( ).Pp .02–.03
These three SNPs are found together on one AA haplotype,
[block 3-0.090], which spans 2,231 bp (fig. 1 and table 1).
Among EAs from all cohorts combined, no SNPs were sig-
nificant when the 128 HREU individuals were compared
with the 661 HIV-1–positive seroconvertors. When the
EAs were stratified by cohort, the dominant rs2015086
genotype had a frequency of 0.40 in the 25 hemophilic
HREU individuals in the MHCS cohort and a frequency
of 0.18 in the 170 seroconvertors in the MHCS cohort
( ) (tables 4 and 5).Pp .02
The influence of genetic variation in each SNP on dis-
ease progression was assessed. Cox proportional hazards
regression, including CCL5 covariates, showed SNPs
rs1634507 and rs1719146 to be significantly associated
with more-rapid disease progression (to AIDS-93 or AIDS-
87) when 290 AAs from all cohorts were combined (Pp
) (table 3). Among all AAs, rs1719146 was signifi-.03–.05
cantly associated (relative hazard [RH] of 2.97; )Pp .03
when the CCL5 covariates were not included (data not
shown). When the 238 members of ALIVE were examined
separately, only rs1719146 was significantly associated
( ). Cox regression also found six SNPs to be sig-Pp .02
nificantly associated with more-rapid progression to AIDS-
87 and one to AIDS-93, when 661 EAs from all cohorts
combined were examined with CCL5 covariates included
( ) (table 3). Five of the six SNPs associated withPp .01–.04
AIDS-87 are together on a single EA haplotype, [block 3-
0.203], that spans 28,952 bp. The same six SNPs were sig-
nificant ( ; ) among all EAsRHp 1.29–1.39 Pp .005–.03
when the CCL5 covariates were not included (data not
shown). Inspection of the three major EA cohorts indi-
cated that these disease-accelerating effects are largely at-
tributable to the MACS cohort rather than the MHCS,
HGDS, or SFCC cohort (table 3). Eight SNPs were signif-
icantly associated ( ) with AIDS-87 in the MACSPp .01–.04
cohort, whereas none was associated in the MHCS, HGDS,
or SFCC cohort.
The results presented in table 3 were confirmed by Kap-
lan-Meier survival analyses without CCL5 covariates, in
which 10 SNPs were associated with more-rapid disease
progression in all EAs, including 9 SNPs in the MACS co-
hort (results not shown). As illustrated by the graphs in
figure 2, the rate of AIDS-87 disease progression is in-
creased among all EAs carrying one (C/T) or two (T/T)
copies of the variant rs1719130 allele compared with those
carrying the wild-type (C/C) genotype (fig. 2A) and is in-
creased among individuals in the MACS cohort carrying
one (A/T) or two (T/T) copies of the variant rs1719153
allele compared with those homozygous (A/A) for the
wild-type allele (fig. 2B).
Discussion
This study evaluated the role of genetic variation in 21
SNPs in the CCL18, CCL3, and CCL4 chemokine genes in
HIV-1 infection and AIDS disease progression in five U.S.
natural-history AIDS cohorts. There was extensive LD in
the 47,637 bp surveyed in both EAs and AAs but partic-
ularly in EAs, among whom limited allelic and haplotype
diversity was found. Four statistically significant associa-
tions with HIV-1 transmission or AIDS progression were
identified, two of which replicate results of an earlier
study. Importantly, replication has recently been reported
to be the “gold standard” in genetic association studies.31
We further discuss the two replicated associations.
The first was a protective genetic influence on HIV-1
infection for three correlated CCL3 SNPs (ss46566437,
ss46566439, and ss46566438, located on one haplotype
covering 2,231 bp) in AAs from the ALIVE cohort. Al-
though ss46566437 is a nonsynonymous (E79D) substi-
tution, we have no evidence indicating that it is a func-
tional mutation. These results confirm and extend those
of Gonzalez et al.,10 who reported a significantly elevated
frequency of the ss46566438-containing haplotype in HIV-
1–negative AA subjects compared with HIV-1–positive AA
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Figure 2. Kaplan-Meier survival curves showing the dependence
of AIDS-87 progression (the proportion surviving who did not reach
the disease end point) on the dominant rs1719130 genotype in
all EAs (A) and the dominant rs1719153 genotype in the MACS
cohort (B). A, The black curve (C/C) represents all individuals
homozygous for the wild-type allele, and the blue curve (C/T and
T/T) includes individuals with one or two copies of the minor allele.
The total number of individuals was 636; 291 developed AIDS, and
345 were censored. ; log-rank ; WilcoxonRHp 1.50 Pp .0065
; 2log(likelihood ratio) . B, The black curvePp .0023 Pp .009
(A/A) represents individuals carrying two copies of the wild-
type allele, and the blue curve (A/T and T/T) represents individuals
with one or two copies of the variant allele. The total number
of individuals was 402; 184 developed AIDS, and 218 were cen-
sored. ; log-rank ; Wilcoxon ;RHp 1.51 Pp .0072 Pp .0159
2log(likelihood ratio) . RH values were obtained fromPp .0149
Cox proportional hazards regression, and the P values were ob-
tained from the Kaplan-Meier survival analyses.
subjects. The protective effect found in our study was
slightly stronger for the ALIVE cohort alone (odds ratio
[OR] 0.47) than for all AAs combined (OR 0.57). This may
be a result of mode of infection, sampling artifacts, or
population stratification. ALIVE is an injection-drug-user
cohort from Baltimore. The second largest population of
AA participants consists of 45 seroconvertors from the
MACS, a cohort of homosexual men from four American
cities.18 It is well established that AAs are admixed and
that different populations may have different ancestral
African and European genetic contributions.32 It is thus
expected that different genetic backgrounds will reveal
varying susceptibility to infectious agents.
Second, we found that each of seven highly correlated
SNPs was associated with more-rapid disease progression
in EAs. These SNPs span 36,562 bp and contain all three
genes. Given the extensive disequilibrium in the region,
it is not possible to identify a particular SNP or even a
single gene as causative. Although CCL18 has not yet been
implicated in HIV-1/AIDS pathogenesis and its receptor is
not known,33 the present genetic analysis cannot rule out
this gene as a candidate for modulating HIV-1–related
pathogenesis. Furthermore, pairwise protein alignment
scores obtained using CLUSTALW34 were 54.4 for CCL3
and CCL4, 59.6 for CCL3 and CCL18, and 40.5 for CCL4
and CCL18. The high relative score for alignment between
CCL3 and CCL18 suggests that there could be some re-
dundancy in receptor binding between these two ligands.
Importantly, this disease-accelerating association supports
an earlier study in which borderline statistical significance
( ) in Kaplan-Meier survival analysis of an EAPp .03–.09
population was reported for rs1719134.10 Interestingly, the
level of LD in the present study is comparable to what
was reported for the CCL2-CCL7-CCL11 chemokine gene
cluster, which is 1.8 Mb upstream of the CCL18-CCL3-
CCL4 cluster.25 In that region, a 31-kb haplotype contain-
ing all three genes was associated with decreased suscep-
tibility to infection among EAs. Similar to the findings
here, a single gene or SNP could not be singled out as
being responsible for the association, given the observed
extent of LD.
Although significant Cox regression P values were ob-
served for EAs in the MACS cohort but not in the other
cohorts, the RH values for these cohorts overlapped each
other. Thus, the smaller P values for the MACS EAs may
be influenced by the larger sample size. The MACS and
SFCC cohorts consist of men who became infected with
HIV-1 through unprotected anal intercourse, whereas the
MHCS participants have hemophilia and were exposed to
HIV-1–contaminated clotting factor; thus, route of infec-
tion does not seem to explain differences between cohorts
in the association results. On the other hand, the DNA
samples used in this study from the MHCS and the SFCC
cohorts are enriched for long-term nonprogressors and
thus represent a nonrandom segment of the population
surviving with HIV-1 infection, whereas the MACS sam-
ples are a broader representation of the infected popula-
tion.18 In other words, if people developing AIDS early
after infection had been recorded by the MHCS and SFCC
cohorts, then perhaps their disease-progression profiles
would be more similar to that of the MACS cohort.
CCR5 binding ligands such as CCL3, CCL4, and CCL5
can limit HIV-1 infection via at least three different mech-
anisms. After a ligand binds to its receptor, the viral en-
velope protein is blocked from attaching to the cell. A
second possibility is that the chemokines induce endo-
cytosis of the receptor, thus limiting availability of the
receptor to virus.35,36 It has also been suggested that che-
mokines can induce receptor dimerization that subse-
quently prevents viral proteins from interacting with the
cellular membrane.37 Further, it has been shown that
the ability of CCL5 to limit HIV-1 infection can vary be-
tween cell types.38 In addition, gene-by-gene and gene-
by-environment interactions certainly act on HIV-1/AIDS
pathology, as do various social and environmental var-
iables.39 The idea that certain genotypes act only under
specific environmental conditions or that a given geno-
type may produce different phenotypes in different en-
vironments is a distinct possibility.31 These interactions
are more complex than was initially anticipated, rein-
forcing the need for further study and emphasizing the
importance of replication among studies with adequate
power.
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